Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa

Randomised Double Blind Crossover Placebo Controlled Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00336154

Enrollment

Registered

2006-06-13

Start date

Unknown

Completion date

Unknown

Last updated

2020-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epidermolysis Bullosa

Brief summary

Epidermolysis Bullosa(EB) is an inherited bullous disease. Tetracycline is believed to have anti inflammatory properties. 20 patients with EB older than 13 years will be treated for 4 months with tetracycline or placebo. After one month of wash out they will be treated for additional 4 m with placebo or tetracycline. The patients will be examined each month to estimate bulla formation,rate of healing .

Detailed description

Interventions

DRUGtetracyclin

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

13 Years to 60 Years

Healthy volunteers

Inclusion criteria

* diagnosed as epidermolysis bullosa * not pregnant * active disease * more than 5 bulla-

Exclusion criteria

* age less than 13 * known sensitivity to tetracyclin * abnormal liver and kidney tests.

Design outcomes

Primary

Measure	Time frame
no of blisters	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026